Abstract
Major depressive disorder (MDD) is associated with a significant burden and costs to the society. As remission of depressive symptoms is achieved in only one-third of the MDD patients after the first antidepressant trial, unsuccessful treatments contribute largely to the observed suffering and social costs of MDD. The present article provides a summary of the therapeutic strategies that have been tested for treatment-resistant depression (TRD). A computerized search on MedLine/PubMed database from 1975 to September 2014 was performed, using the keywords “treatment-resistant depression”, “major depressive disorder”, “adjunctive”, “refractory” and “augmentation”. From the 581 articles retrieved, two authors selected 79 papers. A manual searching further considered relevant articles of the reference lists. The evidence found supports that adding or switching to another antidepressant from a different class is an effective strategy in more severe MDD after failure to an initial antidepressant trial. Also, in subjects resistant to two or more classes of antidepressants, some augmentation strategies and antidepressant combinations should be considered, although the overall response and remission rates are relatively low, except for fast acting glutamatergic modulators. The wide range of available treatments for TRD reflects the complexity of MDD, which does not underlie diverse key features of the disorder. Larger and well-designed studies applying dimensional approaches to measure efficacy and effectiveness are warranted.
Keywords: Antidepressant, antipsychotic, diagnosis treatment, glutamate, monoamines, major depressive disorder.
Current Neuropharmacology
Title:Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
Volume: 13 Issue: 5
Author(s): Rafael T. de Sousa, Marcus V. Zanetti, Andre R. Brunoni and Rodrigo Machado-Vieira
Affiliation:
Keywords: Antidepressant, antipsychotic, diagnosis treatment, glutamate, monoamines, major depressive disorder.
Abstract: Major depressive disorder (MDD) is associated with a significant burden and costs to the society. As remission of depressive symptoms is achieved in only one-third of the MDD patients after the first antidepressant trial, unsuccessful treatments contribute largely to the observed suffering and social costs of MDD. The present article provides a summary of the therapeutic strategies that have been tested for treatment-resistant depression (TRD). A computerized search on MedLine/PubMed database from 1975 to September 2014 was performed, using the keywords “treatment-resistant depression”, “major depressive disorder”, “adjunctive”, “refractory” and “augmentation”. From the 581 articles retrieved, two authors selected 79 papers. A manual searching further considered relevant articles of the reference lists. The evidence found supports that adding or switching to another antidepressant from a different class is an effective strategy in more severe MDD after failure to an initial antidepressant trial. Also, in subjects resistant to two or more classes of antidepressants, some augmentation strategies and antidepressant combinations should be considered, although the overall response and remission rates are relatively low, except for fast acting glutamatergic modulators. The wide range of available treatments for TRD reflects the complexity of MDD, which does not underlie diverse key features of the disorder. Larger and well-designed studies applying dimensional approaches to measure efficacy and effectiveness are warranted.
Export Options
About this article
Cite this article as:
de Sousa Rafael T., V. Zanetti Marcus, R. Brunoni Andre and Machado-Vieira Rodrigo, Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics, Current Neuropharmacology 2015; 13 (5) . https://dx.doi.org/10.2174/1570159X13666150630173522
| DOI https://dx.doi.org/10.2174/1570159X13666150630173522 |
Print ISSN 1570-159X |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances and Integrative Approaches to Gut-Brain Interactions
Disorders of gut-brain interaction (DGBIs), formerly known as functional gastrointestinal disorders, involve dysfunction of complex signaling pathways between the gastrointestinal tract and the central nervous system. These disorders span the esophagus (functional heartburn, functional dysphagia), stomach (functional dyspepsia), and intestines (irritable bowel syndrome, chronic constipation), and are increasingly recognized as ...read more
Advances in Neuroimaging: Bridging Pharmacology, Nanotechnology, and Neurological Disorders
This special topic seeks to compile cutting-edge research and reviews that explore the synergy between neuroimaging, pharmacology, and nanotechnology in understanding and treating neurological disorders. We aim to elucidate novel imaging biomarkers for tracking drug efficacy and disease progression in conditions such as Alzheimer’s, Parkinson’s, multiple sclerosis, and brain tumors. ...read more
Advances in Neurovascular Unit in Stroke and Neurodegenerative Disease: Mechanisms and Therapeutic Frontiers
The main goal of this special issue is to analyze current knowledge of the functional roles of various types of cells in neurovascular units(NVU) in neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. This issue invites research on the cellular and molecular mechanisms driving inflammation, blood-brain barrier(BBB) injury, ...read more
Cannabinoids in Health and Disease.
The role of cannabinoids in human physiology and disease has become a dynamic and rapidly evolving field of research, offering new insights into the potential of these compounds. With advancements in neuropharmacology and clinical trials, cannabinoids are now at the forefront of innovative approaches to treat several conditions. This special ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Impact of Ancillary Subunits on Small-Molecule Interactions with Voltage-Gated Potassium Channels
Current Pharmaceutical Design Clinical Trials for Neuroprotection in ALS
CNS & Neurological Disorders - Drug Targets Blood-Brain Barrier Changes in High Altitude
CNS & Neurological Disorders - Drug Targets Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design The Infectious Etiology of Alzheimer’s Disease
Current Neuropharmacology Recent Inventions on Receptor Tyrosine Kinase RET Modulation
Recent Patents on Biotechnology Valproate Induced Acute Pancreatitis - A Unique Case Report
Current Drug Safety Gene and Gene-Environment Risk Factors in Sudden Undexpected Death in Infants
Current Pediatric Reviews Studies on Target Genes of General Anesthetics
Current Drug Targets Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Triggers of Cell Death in the Developing Brain
Current Pediatric Reviews The Medical and Medico-legal Complications of Bulimia Nervosa : Treatments and Complications
Current Women`s Health Reviews Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science Transglutaminases - Possible Drug Targets in Human Diseases
Current Drug Targets - CNS & Neurological Disorders Evaluation of Clozapine-induced Toxicities in Psychic Patients in Mental Health Care Hospitals in the Southern Region of the Saudi Arabia Kingdom
Current Drug Therapy The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Complications of Serogroup B Meningococcal Disease in Survivors: A Review
Infectious Disorders - Drug Targets Recent Development in Neuronal Migration Disorders: Clinical, Neuroradiologic and Genetics Aspects
Current Pediatric Reviews Neurotransmitter Effects in Human Immunodeficiency Virus (HIV) and Simian Immuno-Deficiency Virus (SIV) Infection
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology





